ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML).
Standard
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). / Zander, A R; Kröger, N; Schleuning, M; Finke, J; Zabelina, Tatjana; Beelen, D; Schwerdtfeger, R; Baurmann, H; Bornhäuser, M; Ehninger, G; Fauser, A A; Kiehl, M; Trenschel, R; Ottinger, H D; Bertz, H; Berger, J; Kolb, H-J; Schaefer, U W.
In: BONE MARROW TRANSPL, Vol. 32, No. 4, 4, 2003, p. 355-361.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML).
AU - Zander, A R
AU - Kröger, N
AU - Schleuning, M
AU - Finke, J
AU - Zabelina, Tatjana
AU - Beelen, D
AU - Schwerdtfeger, R
AU - Baurmann, H
AU - Bornhäuser, M
AU - Ehninger, G
AU - Fauser, A A
AU - Kiehl, M
AU - Trenschel, R
AU - Ottinger, H D
AU - Bertz, H
AU - Berger, J
AU - Kolb, H-J
AU - Schaefer, U W
PY - 2003
Y1 - 2003
N2 - Matched unrelated donor transplants have an increased risk of severe graft-versus-host disease and transplant-related mortality (TRM). ATG has been introduced to decrease GvHD and to facilitate engraftment. We conducted a retrospective analysis of 333 patients with chronic myelogenous leukemia, who were treated with Fresenius ATG (n=145, average=90 mg/kg bw, range 40-90 mg/kg bw) or standard immunosuppression without ATG (n=188). Both groups were comparable regarding distribution of age, sex, HLA-matched vs mismatched donors. ATG Fresenius led to a faster leukocyte engraftment, decreased the incidence of acute GvHD and TRM (P=0.01 and P=0.03) and led to a significant better overall survival (70 vs 57%, P=0.03). We concluded that a prospective randomized study is needed to evaluate the definite role of ATG in hemopoietic stem cell transplantation.
AB - Matched unrelated donor transplants have an increased risk of severe graft-versus-host disease and transplant-related mortality (TRM). ATG has been introduced to decrease GvHD and to facilitate engraftment. We conducted a retrospective analysis of 333 patients with chronic myelogenous leukemia, who were treated with Fresenius ATG (n=145, average=90 mg/kg bw, range 40-90 mg/kg bw) or standard immunosuppression without ATG (n=188). Both groups were comparable regarding distribution of age, sex, HLA-matched vs mismatched donors. ATG Fresenius led to a faster leukocyte engraftment, decreased the incidence of acute GvHD and TRM (P=0.01 and P=0.03) and led to a significant better overall survival (70 vs 57%, P=0.03). We concluded that a prospective randomized study is needed to evaluate the definite role of ATG in hemopoietic stem cell transplantation.
M3 - SCORING: Zeitschriftenaufsatz
VL - 32
SP - 355
EP - 361
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 4
M1 - 4
ER -
